A phase 3, randomized, double-blind study of ceftobiprole versus vancomycin in the treatment of complicated skin and skin structure infections
- Conditions
- Suspected or proven complicated skin and soft tissues infections, caused by staphilococcus metcillin resistant species (MRSS), Metcillin Staphilococcus Aureus Resistant (MTSA) included.MedDRA version: 6.1Level: HLGTClassification code 10040792
- Registration Number
- EUCTR2004-001662-41-IT
- Lead Sponsor
- BASILEA PHARMACEUTICA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method